The impact of statins, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (ARBs) on coronavirus disease 2019 (COVID-19) severity and recovery is important given their high prevalence of use among individuals at risk for severe COVID-19. We studied the association between use of statin/angiotensin-converting enzyme inhibitors/ARB in the month before hospital admission, with risk of severe outcome, and with time to severe outcome or disease recovery, among patients hospitalized for COVID-19. We performed a retrospective single-center study of all patients hospitalized at University of California San Diego Health between February 10, 2020 and June 17, 2020 (n = 170 hospitalized for COVID-19, n = 5,281 COVID-negative controls). Logistic regression and competing risks analyses were used to investigate progression to severe disease (death or intensive care unit admission), and time to discharge without severe disease. Severe disease occurred in 53% of COVID-positive inpatients. Median time from hospitalization to severe disease was 2 days; median time to recovery was 7 days. Statin use prior to admission was associated with reduced risk of severe COVID-19 (adjusted OR 0.29, 95%CI 0.11 to 0.71, p < 0.01) and faster time to recovery among those without severe disease (adjusted HR for recovery 2.69, 95%CI 1.36 to 5.33, p < 0.01). The association between statin use and severe disease was smaller in the COVID-negative cohort (p for interaction = 0.07). There was potential evidence of faster time to recovery with ARB use (adjusted HR 1.92, 95%CI 0.81 to 4.56). In conclusion, statin use during the 30 days prior to admission for COVID-19 was associated with a lower risk of developing severe COVID-19, and a faster time to recovery among patients without severe disease.

他汀类药物，血管紧张素转化酶抑制剂和血管紧张素II受体阻滞剂（ARBs）对冠状病毒病2019（COVID-19）严重程度和恢复的影响非常重要，因为它们在有严重COVID-19风险的个体中普遍使用。我们研究了在住院COVID-19的患者中，入院前一个月使用他汀/血管紧张素转换酶抑制剂/ ARB与严重后果风险，严重后果或疾病恢复时间之间的关系。我们对2020年2月10日至2020年6月17日在加利福尼亚大学圣地亚哥健康分校住院的所有患者进行了一项回顾性单中心研究（n = 170的COVID-19住院患者，n = 5,281的COVID阴性对照患者）。使用Logistic回归和竞争风险分析来调查严重疾病的进展（死亡或重症监护病房入院）以及无严重疾病的出院时间。53％的COVID阳性住院患者发生严重疾病。从住院到严重疾病的中位时间为2天。恢复的平均时间为7天。入院前服用他汀类药物与降低严重COVID-19的风险（校正后的OR 0.29，95％CI 0.11至0.71，p <0.01）和无严重疾病的患者恢复时间加快（校正后的HR恢复2.69，95％）相关。 CI 1.36至5.33，p <0.01）。在COVID阴性的人群中，他汀类药物的使用与严重疾病之间的关联较小（相互作用的p = 0.07）。有潜在的证据表明，使用ARB可以使恢复时间更快（HR调整为1.92，95％CI为0.81至4.56）。